<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363022</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ALF-04</org_study_id>
    <nct_id>NCT03363022</nct_id>
  </id_info>
  <brief_title>To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure</brief_title>
  <official_title>To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure- A Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients of Acute liver failure not meeting the KCH (King's College Hospital) criteria/or
      meeting KCH criteria not having option of liver transplant will be recruited for the trial.
      The first group will receive Standard medical care with Fecal Microbiota transplant on Day 1
      for 3 consecutive days. FMT (Fecal Microbiota Transplant) will be delivered rectally which
      will be placed bedside. Suitable donor will be screened and the stool samples will be used as
      per criteria. Stool samples will be taken at the time at Day 0, 1(Post FMT), Day 4, 6, 14,21.
      Sepsis screen will be sent. Inflammatory markers will be sent on Day 0,1, 4,6, 14,21. The
      second group will receive standard medical therapy/and an placebo. Stool samples will be sent
      on Day 0,1, 4, 6 , 14,21. Inflammatory markers will be sent on the time on day 0,1 4,6 ,
      14,21.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in both groups</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of SIRS (Systemic Inflammatory Response Syndrome) in both groups</measure>
    <time_frame>Day 1,2,5,7,14,21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of ammonia in both groups</measure>
    <time_frame>Day 1,2,5,7,14,21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Cerebral edema in both groups</measure>
    <time_frame>Day 1,2,5,7,14,21</time_frame>
    <description>Improvement is defined as transcranial doppler &lt; 0.9/Features suggestive of edema in CT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (Sequential Organ Failure Assessment) Score in both groups</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Liver Failure</condition>
  <arm_group>
    <arm_group_label>Standard Medical Treatment+Fecal Microbiota Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.</description>
    <arm_group_label>Standard Medical Treatment+Fecal Microbiota Transplant</arm_group_label>
    <arm_group_label>Standard Medical Treatment+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Microbiota Transplant</intervention_name>
    <description>Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of âˆ¼50 g will be considered adequate.
250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.
Enema to be held for 30 minutes.</description>
    <arm_group_label>Standard Medical Treatment+Fecal Microbiota Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be identical and non medicinal to the Fecal Microbiota Transplant</description>
    <arm_group_label>Standard Medical Treatment+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Acute liver failure -Not meeting KCH Criteria/Meeting KCH Criteria but not having Liver
        transplant option

        Exclusion Criteria:

          1. Culture Positive Sepsis

          2. History of taking lactulose, rifaximin, neomycin, metronidazole, L-Ornithine
             L-Aspartate

          3. Receiving psychoactive drugs, promotility and hypomotility drugs

          4. Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Harsh Vardhan Tevethia, MD</last_name>
    <phone>01146300000</phone>
    <email>Hershey4686@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

